Lucid Diagnostics (NASDAQ:LUCD) Issues Earnings Results, Misses Estimates By $0.03 EPS

Lucid Diagnostics (NASDAQ:LUCD) released its earnings results on Thursday. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03), FiscalAI reports. The company had revenue of $1.50 million for the quarter, compared to analyst estimates of $1.39 million.

Here are the key takeaways from Lucid Diagnostics’ conference call:

• Lucid secured a VA Federal Supply Schedule (FSS) contract for EsoGuard at a Medicare-aligned price (~$1,938), opening access to ~170 VA medical centers and a clinically relevant 9M‑patient veteran population.
• Commercial traction accelerated in Q4 with 3,664 tests (above the 2,500–3,000 target), a 29% sequential volume increase and $1.5M of recognized revenue (24% sequential growth).
• Largest real‑world study to date (~12,000 at‑risk patients) showed strong operational performance for EsoCheck/EsoGuard — 95% technical success, 95% of procedures <2 minutes and 100% safety — supporting scalability and payer discussions.
• Management expects a draft Medicare LCD soon after favorable MolDX engagement (followed by a 45‑day public comment period); final coverage would enable retroactive Medicare payments but timing remains uncertain.
• Liquidity and dilution risk: year‑end cash was $34.7M with an average burn of ~$11.1M/quarter, and upcoming Series B conversions will materially increase share count, implying funding/OpEx discipline is required.

Lucid Diagnostics Trading Down 2.6%

Shares of NASDAQ LUCD opened at $1.12 on Friday. The company has a market capitalization of $154.20 million, a P/E ratio of -1.17 and a beta of 1.18. Lucid Diagnostics has a 12 month low of $0.95 and a 12 month high of $1.80. The stock has a 50 day moving average of $1.30 and a 200-day moving average of $1.18.

Analysts Set New Price Targets

A number of research firms have recently commented on LUCD. Ascendiant Capital Markets increased their price objective on shares of Lucid Diagnostics from $8.00 to $8.25 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. Needham & Company LLC restated a “buy” rating and set a $3.00 target price on shares of Lucid Diagnostics in a report on Thursday. Wall Street Zen raised shares of Lucid Diagnostics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Lucid Diagnostics currently has a consensus rating of “Moderate Buy” and a consensus target price of $3.94.

Key Stories Impacting Lucid Diagnostics

Here are the key news stories impacting Lucid Diagnostics this week:

• Positive Sentiment: Won expanded access with the U.S. Department of Veterans Affairs and is pushing for Medicare/commercial payer wins, which could materially enlarge addressable market and reimbursement prospects. Lucid Diagnostics signals expanded VA market access and 29% sequential test volume
• Positive Sentiment: Strong test-volume growth: management reported ~29% sequential growth in EsoGuard tests processed (3,664 tests in Q4), indicating improving commercial traction. Q4 2025 Earnings Call Highlights
• Positive Sentiment: Revenue slightly beat consensus ($1.50M reported vs. $1.39M expected), showing top-line improvement versus prior-year quarter. Zacks: Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Company highlighted strengthened clinical evidence with positive real‑world data (largest reported experience for esophageal precancer detection), which can support adoption and payer discussions. PR Newswire: Business Update & Financial Results
• Positive Sentiment: Analyst backing: Needham reaffirmed a “buy” rating with a $3.00 price target, representing sizable upside from current levels if execution continues. Benzinga: Needham Reaffirms Buy
• Neutral Sentiment: Company hosted a Q4 business update and provided slides/webcast; multiple earnings-call transcripts and slides are available for investors evaluating management commentary and forward guidance. Quarterly Press Release / Slide Deck
• Negative Sentiment: Earnings miss on profitability: Lucid reported a Q4 EPS of -$0.10 vs. consensus -$0.07, a larger-than-expected loss that likely drove near-term selling pressure despite revenue strength. InsiderMonkey: Q4 2025 Earnings Call Transcript

Hedge Funds Weigh In On Lucid Diagnostics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of Lucid Diagnostics by 9.6% during the 3rd quarter. Vanguard Group Inc. now owns 4,523,997 shares of the company’s stock worth $4,569,000 after buying an additional 396,719 shares during the last quarter. Masters Capital Management LLC grew its stake in Lucid Diagnostics by 46.6% in the 3rd quarter. Masters Capital Management LLC now owns 3,999,273 shares of the company’s stock valued at $4,039,000 after buying an additional 1,272,000 shares during the last quarter. Two Seas Capital LP bought a new position in Lucid Diagnostics in the 3rd quarter valued at about $3,030,000. Geode Capital Management LLC lifted its position in Lucid Diagnostics by 21.1% during the fourth quarter. Geode Capital Management LLC now owns 2,026,827 shares of the company’s stock worth $2,209,000 after acquiring an additional 352,654 shares during the last quarter. Finally, Alyeska Investment Group L.P. lifted its position in Lucid Diagnostics by 87.3% during the third quarter. Alyeska Investment Group L.P. now owns 1,383,116 shares of the company’s stock worth $1,397,000 after acquiring an additional 644,839 shares during the last quarter. 74.01% of the stock is currently owned by institutional investors and hedge funds.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.